Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Young‐Kwang Yoon
Observed name:
Young-Kwang Yoon
Institution:
Genome and Company (South Korea)
Observed institutions:
AstraZeneca (United Kingdom),
Seoul National University,
Asan Medical Center,
Seoul National University Hospital,
University of Ulsan,
Genome and Company (South Korea),
Hanmi Pharmaceutical (South Korea)
show all 7
ORCID:
0000-0002-7357-5724
Observed ORCID:
0000-0002-7357-5724
OpenAlex ID:
A5036241941
RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
2013
·
Ahrum Min
, Seock-Ah Im
, et al.
·
Molecular Cancer Therapeutics
·
146
KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach
2010
·
Young‐Kwang Yoon
, Hwang‐Phill Kim
, et al.
·
Molecular Carcinogenesis
·
135
Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
2009
·
Hwang-Phill Kim
, Young-Kwang Yoon
, et al.
·
PLoS ONE
·
122
PDF
The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines
2008
·
Jin Won Kim
, Hwang-Phill Kim
, et al.
·
Cancer Letters
·
119
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells
2009
·
Young-Kwang Yoon
, Hwang-Phill Kim
, et al.
·
Molecular Cancer Therapeutics
·
74
Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer
2012
·
Hyun-Jin Nam
, Seock-Ah Im
, et al.
·
Molecular Cancer Therapeutics
·
66
RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase
2010
·
Kyung-Hun Lee
, Hyung-Seok Hur
, et al.
·
Cancer Letters
·
56
Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer
2011
·
Hyun-Jin Nam
, Hwang-Phill Kim
, et al.
·
Cancer Letters
·
54
Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers
2012
·
Jiyeon Yun
, Sang-Hyun Song
, et al.
·
Laboratory Investigation
·
46
PDF
HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF
2017
·
Jae Ho Jeong
, Jihun Kim
, et al.
·
Clinical Colorectal Cancer
·
44
Heterodimerization of Glycosylated Insulin-Like Growth Factor-1 Receptors and Insulin Receptors in Cancer Cells Sensitive to Anti-IGF1R Antibody
2012
·
Jun Gyu Kim
, Min Jueng Kang
, et al.
·
PLoS ONE
·
44
PDF
Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells
2011
·
Hye Jin Kim
, Hwang-Phill Kim
, et al.
·
Anti-Cancer Drugs
·
25
The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines
2011
·
Hyun-Jin Nam
, Hwang-Phill Kim
, et al.
·
Investigational New Drugs
·
17
Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center
2019
·
Kyoungmin Lee
, So Jung Lee
, et al.
·
PLoS ONE
·
15
PDF
Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
2017
·
Dalyong Kim
, Sun Young Kim
, et al.
·
BMC Gastroenterology
·
15
PDF
Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer
2012
·
Young-Kwang Yoon
, Seock-Ah Im
, et al.
·
Cancer Letters
·
15
Establishment of Kawasaki disease database based on metadata standard
2016
·
Yu Rang Park
, Jae-Jung Kim
, et al.
·
Database
·
8
PDF
Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells
2011
·
Young-Kwang Yoon
, Hwang-Phill Kim
, et al.
·
Cancer Letters
·
8
Phase II study of GEN-001 in combination with avelumab in patients with PD-L1–positive locally advanced, or metastatic gastric cancer (GC) or gastroesophageal junction cancer (GEJC) who have progressed after second-line (2L) and beyond (GEN001-201 study).
2024
·
Jeeyun Lee
, Minkyu Jung
, et al.
·
Journal of Clinical Oncology
·
4
Expedited Safety Reporting to Sponsors Through the Implementation of an Alert System for Clinical Trial Management at an Academic Medical Center: Retrospective Design Study
2019
·
Yu Rang Park
, HaYeong Koo
, et al.
·
JMIR Medical Informatics
·
2
PDF
Abstract 5479: Antitumor effect of KX-01, a novel Src and tubulin inhibitor, in triple negative breast cancer cells
2014
·
Seongyeong Kim
, Seock-Ah Im
, et al.
·
Cancer Research
·
1
Abstract 1775: Growth inhibitory effect of PARP inhibitor olaparib in gastric cancer cells
2010
·
Seock-Ah Im
, Ahrum Min
, et al.
·
Cancer Research
·
1
Supplementary Methods from Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer
2023
·
Hyun-Jin Nam
, Seock-Ah Im
, et al.
Supplementary Figure 4 from Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer
2023
·
Hyun-Jin Nam
, Seock-Ah Im
, et al.
PDF
Supplementary Figure 3 from Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer
2023
·
Hyun-Jin Nam
, Seock-Ah Im
, et al.
Show more works
View as search
Works count:
42
Citation count:
1,017
H-index:
15
I10-index:
16
Year
Topic
Type
